Carbapenem-based Antibiotics Market: Quantitative Market Analysis, Current and Future Trends

Carbapenem-Based Drugs Industry Analysis, Opportunity Assessment and Forecast up to 2031 The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Carbapenem-Based Drugs market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Carbapenem-Based Drugs The report offers actionable and valuable market insights of Carbapenem-Based Drugs.

The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Carbapenem-Based Drugs Market across various industries and regions.

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=4425 This newly published and insightful report sheds light on Market Insights of Carbapenem-Based Drugs, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Carbapenem-Based Drugs Market.

Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 – 2021.

Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of patent for ertapenem is expected to offer new avenues for market growth in regulated as well as non-regulated carbapenem-based antibiotics market where its adoption & availability are comparatively limited. On the back of these factors, the global carbapenem-based antibiotics market is estimated to reach a valuation of US$1.8 Bn by 2029.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425

Key Takeaways of Carbapenem-based Antibiotics Market Study 

Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.



Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.



Currently, the carbapenem-based antibiotics market is dominated by ertapenem.

However, tebipenem is expected to gain traction during the forecast period in terms of revenue.



In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.

“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.

Strategic Expansion by Dominant Players Benefiting Market The carbapenem-based antibiotics market is dominated by top three players including Merck Co. & Inc., Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. These leading players in the carbapenem-based antibiotics market contribute around 80% to 90% revenue share. Clinical stage companies such as Spero Therapeutic Inc. and Iterum Therapeutics Inc. with the launch of their novel carbapenem-based antibiotics are expected to acquire significant market space.

In October 2017, Spero Therapeutics, Inc. and Meiji Seika Pharma Co., Ltd. announced an exclusive licensed partnership for its carbapenem-based antibiotic named SPR994 (tebipenem). In a similar development, Sumitomo Dainippon Pharma in June 2017, announced a partnership with Zuellig Pharma for sales of carbapenem-based antibiotic meropenem in five countries of Southeast Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4425 Key Question answered in the survey of Carbapenem-Based Drugs market report:  Sales and Demand of Carbapenem-Based Drugs 

Growth of Carbapenem-Based Drugs Market



Market Analysis of Carbapenem-Based Drugs



Market Insights of Carbapenem-Based Drugs



Key Drivers Impacting the Carbapenem-Based Drugs market



Which are the Key drivers impacted by Carbapenem-Based Drugs market



Restraints Shaping Market Growth



Market Survey of Carbapenem-Based Drugs

More Valuable Insights on Carbapenem-Based Drugs Market Fact.MR, in its new report, offers an unbiased Market Analysis of Carbapenem-Based Drugs, Sales and Demand of Carbapenem-Based Drugs, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Read More Trending Reports of Fact.MRhttps://www.prnewswire.com/news-releases/respiratory-virus-vaccines-rdfocused-on-covid-19-efforts-factmr-301230897.html About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from

automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates Email: sales@factmr.com Visit Our Website: https://www.factmr.com